Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector
- *Departments of Medicine and Molecular & Cellular Biology, Division of Endocrinology and Metabolism, and §Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030
-
Communicated by Bert W. O'Malley, Baylor College of Medicine, Houston, TX (received for review August 27, 2001)
Abstract
Ideally, somatic gene therapy should result in lifetime reversal of genetic deficiencies. However, to date, phenotypic correction of monogenic hyperlipidemia in mouse models by in vivo gene therapy has been short-lived and associated with substantial toxicity. We have developed a helper-dependent adenoviral vector (HD-Ad) containing the apolipoprotein (apo) E gene. A single i.v. injection of this vector completely and stably corrected the hypercholesterolemia in apoE-deficient mice, an effect that lasted the natural lifespan of the mice. At 2.5 years, control aorta was covered 100% by atherosclerotic lesion, whereas aorta of treated mice was essentially lesion-free. There was negligible toxicity associated with the treatment. We also developed a method for repeated HD-Ad vector administration that could be applied to organisms, e.g., humans, with life spans longer than 2–3 years. These studies indicate that HD-Ad is a promising system for liver-directed gene therapy of metabolic diseases.
Footnotes
-
↵ † Present address: Division of Basic Science, National Cancer Center, Koyang, Kyonggi, 411-764 Korea.
-
↵ ‡ Present address: Department of Vascular Surgery, Allgemeinen Krankenhaus (AKH), University of Vienna, Warhringer Guerte, 18-20, A-1090 Austria.
-
↵ ¶ To whom reprint requests should be addressed. E-mail: lchan{at}bcm.tmc.edu.
- Abbreviations:
- apo,
- apolipoprotein;
- AAV,
- adeno-associated viral vector;
- FG-Ad,
- first-generation adenoviral vector;
- HD-Ad,
- helper-dependent adenoviral vector
- Copyright © 2001, The National Academy of Sciences
